These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37280381)

  • 21. A novel mouse model of familial combined hyperlipidemia and atherosclerosis.
    Chen MJ; Xu YT; Sun L; Wang ZH; Little PJ; Wang L; Xian XD; Weng JP; Xu SW
    Acta Pharmacol Sin; 2024 Jun; 45(6):1316-1320. PubMed ID: 38459255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
    van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease.
    Weintraub SF; Schillow JA; Azari BM; Hirsh BJ
    JACC Case Rep; 2022 Oct; 4(20):1327-1330. PubMed ID: 36299643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.
    Stein R; Ferrari F; Scolari F
    Curr Cardiol Rep; 2019 Jun; 21(8):68. PubMed ID: 31227920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
    Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updates in Small Interfering RNA for the Treatment of Dyslipidemias.
    Carugo S; Sirtori CR; Gelpi G; Corsini A; Tokgozoglu L; Ruscica M
    Curr Atheroscler Rep; 2023 Nov; 25(11):805-817. PubMed ID: 37792132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of PCSK9 in lipid metabolism and atherosclerosis.
    Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
    Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W; Le May C; Cariou B
    Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Therapies for Primary Hyperlipidemia.
    Aguilar-Salinas CA; Gómez-Díaz RA; Corral P
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1216-1224. PubMed ID: 34888679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
    Filippatos TD; Liontos A; Christopoulou EC; Elisaf MS
    Curr Vasc Pharmacol; 2019; 17(4):332-340. PubMed ID: 29424317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
    Surma S; Romańczyk M; Filipiak KJ
    Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
    Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.